Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1

Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test

“…GLP-1 mimetics have been of considerable focus for therapeutic control of glucose (9,10 ), as have mechanisms that increase active GLP-1 concentrations [such as inhibitors of dipeptidyl peptidase (DPP)-4] ( [11][12][13]. Oxyntomodulin is an agonist of both the GLP-1 and glucagon receptors (14 ) and has been investigated as a therapeutic for diabetes and obesity (15)(16)(17). Whereas GLP-1 and oxyntomodulin are produced primarily by intestinal L-cells, glucagon is produced primarily by pancreatic ␣-cells and works as an agonist of the glucagon receptor to increase hepatic glucose production (18 -20 ).…”

Potential of pharmacological modulation of level and activity of incretins in diabetes mellitus type 2

“…For exam ple, the long acting GIP analogue AC163794 increased insulin secretion in healthy and diabetic rats. A small pilot study of this compound in patients with type 2 diabetes confirmed the prolonged effect on insulin secretion [56]. [57].…”

Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2

“…Так, длительно-действующий аналог ГИП AC163794 усиливал секрецию инсулина у здоровых и диабетических крыс. Кроме того проведено небольшое пилотное испытание соединения у пациентов с СД типа 2, в ходе которого подтверждено пролонгированное действие на секрецию инсулина [56].…”

“…Создание двойного агониста позволит уменьшить число побочных эффектов со стороны желудочно-кишечного тракта (ГИП не влияет на перистальтику кишечника) [56].…”